

A research study on Multifunctional Nanomaterials and Nanoparticles for Diagnosis and Therapy

Babar Shahzad,²Umar Tipu,³Dr Areeba Mehboob Sheikh,⁴Qamar Abbas,⁵Dr Zunaira Andleeb,⁶Dr Maryam Tariq Mir

¹UHS, Lahore

²PIMS Islamabad

³Ajk MC

⁴PIMS Islamabad

⁵Chandka medical college smbbmu Larkana

⁶Mohi ud Din Islamic Medical College Mirpur AJK

Abstract:

Retinoblastoma is an uncommon kind of cancer that is difficult to diagnose and cure because of factors such as alterations in tumour-suppressor genes and a lack of focused, effective, and costefficient treatments. Because of its potential for binding to the overexpressed retinoblastoma gene and delivering anticancer drugs in a targeted and regulated fashion, nanotechnology has revolutionized the medical field and opened up new avenues for the diagnosis and treatment of this deadly malignancy. Significant advancements have been achieved in the treatment of retinoblastoma as a result of the use of nanotechnology. These contributions have shown themselves as surface-tailored multi-functionalized nanocarriers, nanocarriers based on lipids, nanocarriers ligands for overexpressed receptors, and metallic nanocarriers, among other forms. It has been shown that every one of these nanocarriers is effective. These nanocarriers seem to be state-of-the-art in the reduction of a broad variety of malignant retinoblastoma. This is accomplished by targeted distribution at a particular area, which ultimately leads to programmed death in cancer cells. This is performed by concentrating delivery efforts to a specific location. Despite the growing importance of nanomedicine in cancer treatment, there has been less discussion of the efficacy of these nanoplatforms in identifying and treating ophthalmic malignancies like retinoblastoma. Recent advances and potential future directions for nanotechnology-based intraocular medication delivery and diagnostic systems were discussed in this paper.

Keywords: cancer, retinoblastoma, nanoparticles, tumour

Introduction: Ocular cancer known as retinal astrocytoma (RB) is more prevalent in infants and young children than it is in older children and young adults, with an incidence that ranges from 1 in 15,000 to 1 in 20,000 live births across the globe [1]. RB is more common in infants and young children than it is in older children and young adults. The risk of contracting RB is higher in younger children and babies as compared to older children and young adults. Strabismus and leukocoria are two of the most obvious indications of RB, and both of these may be seen in both eyes. Both of these can also be observed in both eyes. The loss of sight, subsequent tumours in other parts of the body, and even death may result from it if it is not treated early [3,4]. Malignant RB tumours often appear during the first three years of life, and their initiation by somatic inactivation of both RB gene (RB1) alleles [5,6] is the prototypical pattern for hereditary cancers. Due to their origin in the retina's immature cells, RB tumours are highly dependent on the blood supply in order to grow [7].

For children with RB, the usual treatments were external beam radiation, irradiation to cryotherapy, episcleral plaque, photocoagulation, and enucleation [8]. Over the last few years, there have been several breakthroughs in RB management. Intravenous and intraarterial chemotherapies are now the standard treatment for RB [9], replacing radiation therapy as people become more aware of its dangers. Due to factors such as probable systemic toxicity, rapid blood clearance and drug resistance, their

therapeutic use is limited [10]. Cataracts, radiation retinopathies, and facial abnormalities are all negative side effects of the aforementioned modalities that have led to the implementation of new therapy procedures that are more intense and need an integrated approach [3,11].

Standard dosing reduces the clinical efficacy of chemotherapeutic drugs [12-18]. This holds true both for the administration of drugs that are insoluble in water and for the administration of therapies intended for the back of the eye. Ischemia necrosis, orbital fat necrosis, optic nerve atrophy, and changes in ocular mobility are among side effects of chemotherapy that may be mitigated by administering the medicine locally to the eye, especially with alkylating agents [19,20]. The rapid distribution of the aqueous solution of alkylating medicines throughout the orbit, periorbit, and adjacent tissues is likely to blame for these undesired side effects [21]. Because the conjunctival arteries need to be cleaned, it is more difficult to provide medication to the eye. The complexity of the eye's anatomy and physiology, including the blood-retina barrier, the ocular surface epithelium, and the blood-aqueous barrier, may be detrimental to the eye's ability to perform its normal functions [12]. Because of this, the development of efficient delivery transporters is very necessary for RB treatment.

Fluorescein angiography, magnetic resonance imaging (MRI), commutated tomography (CT), and ultrasonography [6] are just some of the diagnostic methods that are often employed to arrive at the conclusion that retinal tumours are the cause of RB. Although there are several ophthalmic imaging options now accessible, ocular molecular imaging is desperately needed since it allows for the detection of eye diseases long before any outward morphological changes become apparent [22]. Ocular molecular imaging is desperately needed, despite the abundance of existing ophthalmic imaging methods. Ocular molecular imaging is urgently required, despite the fact that there is a wide variety of ophthalmic imaging techniques available right now. There is an immediate demand for ocular molecular imaging despite the fact that there is a wide range of ophthalmic imaging options accessible presently to choose from. When compared to more standard imaging approaches, this sort of imaging enables the early identification of eye illnesses. Typically, ocular tumours are detected when they progress beyond the stage when they are just abnormal cells and into the realm of malignant tissue. However, sampling mistakes may lead to erroneously negative specimens [23], and thus knowledge about the histological nature of the ocular malignancy is crucial.

Diagnosing and treating cancer and eye diseases using nanotechnology has grown exponentially in recent years. Nanotechnology-based ocular delivery methods provide a number of benefits over conventional diagnostics and treatments [24-30]. Nanomaterials (NMs) were created to improve the diagnosis, treatment, and therapy of diseases because of their special properties and prospective uses in medicine and biology [31-36]. Drugs, tiny compounds, peptides, nucleic acids, and vaccines are only some of the many examples of substances for which NPs are utilized for efficient delivery at the present time [37]. In comparison to conventional chemotherapeutics, NPs are safer and more effective because of their regulated release, smaller dimensions (on the order of nanometers), and desired therapeutic toxicity [38,39]. This renewed interest in NPs has several applications, including implants, contact lenses containing NPs, films, nanofabricated devices, and custom-designed nanocarriers for ocular medicine delivery [39].

There are a variety of methods for administering NPs to the eye, including topically, particularly, systemically, intravitreally, and suprachoroidal. For this reason, slow-release NPs or NPs that respond to stimuli are best administered suprachoroidal, intravitreally, or particularly. Meanwhile, topical injection is preferable for bioadhesive or fast-uptake NPs [40]. Peptides and protein ligands like transferrin, when combined with NPs, have the ability to boost the conjunctival entrance and transport of the particles [41]. It has been shown that magnetic nanoparticles (NPs) that enclose a pharmacological payload have the potential to improve cellular absorption of the payload [42]. This is something that has been demonstrated. These functionalized NPs have the capability of functioning as an original and useful contrast agent for magnetic resonance imaging (MRI) [40]. There are several benefits of using NPs to transport nucleic acids (such as micro RNAs, RNA, RNS and short-interfering) [43]. Gene transfection with NPs is advantageous because it prevents nucleic acids from attaching to certain cell

surface receptors, which limits off-target effects and lengthens the time period during which gene transfection may take place. They also prevent nucleic acids from being degraded by endogenous nucleases, which is useful for keeping transfected genes alive for longer. In light of this, it is possible that functionalized NPs are excellent vehicles for retinal gene therapy and nucleic acid delivery in the management of a wide range of ocular illnesses, including RB [46,47]. Delivering drugs using nanoparticles is a cutting-edge strategy for treating ocular diseases.

However, there are still a number of obstacles to overcome when using NPs for this purpose [48-56]. First of all, despite their widespread use as medication and gene carriers, NPs have no ocular side effects [12]. In addition, the incubation of certain NPs may take a significant amount of time [57], and the NPs themselves can form insoluble particles and components that are capable of interacting with biological systems [58]. This research article evaluates the current use of NPs in RB and speculates on their potential in the future as diagnostic and therapeutic tools for RB.

Retinoblastoma Diagnosis and the Role of Nanotechnology: It is necessary to manage the risk of intraocular cancer issues and metastatic potential in the same manner as other tumours [9]. Because it is so close to the ocular tissues, early identification of intraocular cancer is crucial for sustaining eyesight [59]. Depending on when they often appear in patients, intraocular tumours may be broken down into two categories: RB in younger patients and ocular melanoma in older patients [60].

RB is a genetic disorder that often affects children under the age of five and is caused by the silencing of the RB gene. This kind of intraocular cancer is more common in underdeveloped nations. Silencing this gene results in a loss of cell cycle control, leading to uncontrolled cell growth [61,62]. In extreme cases, the tumour may spread outside the eye, causing inflammation of the eye. The pleural space, brain, and spinal cord are also potential destinations for RB's spread. Choroid vascular tissue may be invaded and then dispersed to the bone and stem cell reservoir [1].

Ophthalmologists are the medical professionals most likely to examine and image the eye to diagnose RB. Retinal and vitreous space lesions, as well as a big, white to creamy-colored tumour, are typical findings during fundoscopy. Since CT scans are not recommended for children, ultrasonography is utilized to classify and evaluate intraocular malignancies [63–65]. In addition, MRI scans of the brain and orbits are performed to examine the tumor's spread beyond the eyes [66]. Despite the adaptability of ophthalmic imaging techniques, conventional optical and ultrasound imaging are not useful for detecting disorders of the eye before visible morphological alterations have occurred. Contrarily, several diagnostic approaches have been created with the goal of bettering health outcomes. However, there are constraints and limits when using the current methods [67]. Recent research has uncovered a number of novel RB biomarkers, some of which have the potential to be utilised as prognostic variables for diagnosis. These novel RB biomarkers also contribute to our understanding of the aetiology of RB and inform our strategies for diagnosing and treating this disease [68].

Successful treatment of RB relies on early diagnosis [69]. Improved first-stage cancer diagnosis and ongoing therapy monitoring are both possible because to novel molecular contrasting agents and nanomaterials made possible by nanotechnology [15,16,25,27,70]. See Table1 for a summary of recent developments in nanoplatforms that improve upon the picture quality of standard imaging methods [49,50,54,71]. Despite these advancements, not enough research has gone into optimizing conventional ocular imaging methods by using nanoplatforms [72].

Imaging techniques such as MRI, OCT, and ultrasound imaging are some examples. Table 1: Different Nanostructures summary

Structure	Features	Referenc
Carbon	Mesoporous Au nanocages (AuNCs) were coupled with Fe ₃ O ₄ nanoparticles to increase MRI, US and PA for diagnostic and efficiency monitoring purposes..	61

nanomaterials	To quantify DNA methylation levels, carbon nanofilm electrodes were	62
Quantum dots	In the mouse model eyes, QDs on the posterior side of the cornea were retained 3–48 h after cell injection when the endothelium was cryogenically damaged, but this was not the case in the stable control eyes.	63
Magnetic NPs	Nanoparticles showed excellent negative contrast in magnetic resonance imaging (MRI) investigations and proved to be biocompatible without causing cytotoxicity in normal and cancerous cells.	64
Gold nanorods	Employing au nanorods, it has been shown that PT-OCT is an effective tool for visualizing the distribution of exogenous and endogenous absorbers in the mouse retina. This was accomplished by using the technique.	65
Gold nanoclusters	Antigens (MT 1/2 and MT 3) were imaged with a laser spot size as small as 4 m utilizing LA in combination with inductively coupled plasma—mass spectrometry due to the signal amplification given by >500 gold atoms in each nanocluster (ICP-MS).	66
Gold NPs	Due to their specific light absorption properties, the gold NPs given improved the contrast of photoacoustic images taken at tumour sites.	67

Despite a lack of funding for studies in this field, these nanoplatform have shown enormous promise in improving the quality of imaging and detection of retinal illnesses. Use of quantum dots (QDs) in eye imaging has been studied. As well as being optically robust, they may provide multimodal detection [80,81]. Newly discovered therapy for treating corneal endothelium failure involves injecting cultured human corneal endothelial cells (cHCECs) into the anterior chamber. Toda et al., who injected cHCECs and tracked them using semiconductor QDs, are one such group. Researchers tracked the migration and clustering of cHCECs in a mouse model of corneal endothelial dysfunction by injecting QD-labeled cHCECs [77, 82]. Quantification of cHCECs QDs after injection. Cryogenically wounded corneal endothelium in a mouse model clearly retained cHCECs QDs on the posterior surface 3 to 48 h after cell injection, but healthy control eyes did not. When the dots' potential toxicity is taken into account, QDs may prove to be useful contrast agents. AuNPs are an option that has been offered by several researchers.

As a further example, Lapierre-Landry and colleagues [75] carried out the first in vivo phototherapeutic (PT-OCT) investigation of the eye to investigate endogenous (melanin) and exogenous (Au nanorods) absorbers. Optical coherence tomography (OCT) is currently a standard of care in retinal imaging. OCT allows for the noninvasive mapping of tissue architecture, however it cannot be utilized for in vivo molecular imaging due to the lack of specificity of contrasting agents. This sample developed a method called PT-OCT, which is an OCT-based practical methodology, to determine whether absorbers are present. The photothermal signal was separated using animals with pigmented retinas (also known as "pigmented mice") and animals without pigmented retinas (also known as "albino mice"), respectively. After administering systemic injections of gold nanorods in order to investigate the passive aggregation of these particles in the retina, we found that pigmented animals developed lesions consistent with laser-induced choroidal neovascularization. Based on the data presented here, it seems that PT-OCT, in

conjunction with Au nanorods, might be used to investigate the relative abundance of exogenous and endogenous absorbers in mouse eyes.

Altundal et al. [83] investigated the dosimetric potential of using AuNPs or carboplatin-loaded AuNPs through the employment of kV energy external and internal beam irradiation in order to improve the efficacy of radiotherapy for the treatment of ocular malignancies (choroidal melanoma) and RB. Combining radiation treatment for ocular cancer with AuNPs or carboplatin-loaded AuNPs employing kV energy photon beams was projected to result in significant dosage improvements based on the results. To a greater extent than with an external beam, brachytherapy sources may increase the dosage. However, the external beam has the advantage of not having any side effects.

In a previous work [84], researchers used a rabbit model to investigate the efficacy of brachytherapy combined with ultrasonic heating techniques in the presence of AuNPs for treating ocular RB tumours. We used B-mode ultrasound imaging to evaluate the tumour at the beginning and end of the third week. Both groups were examined histopathologically for signs of tumour necrosis. When compared with the other study groups, the combination group had a strikingly different trajectory of relative tumour area changes than the other groups. The results of the histological analysis confirmed the theory that necrosis of live RB cells had occurred. Again and again, Au NPs have shown their worth in a variety of imaging modalities, including ultrasounds. Because of this, AuNPs may serve as a viable substitute for quantum dots. Carbon nanomaterials have recently garnered a lot of attention [85] due to the structural variations between them and the large variety of functionally based electrical and chemical properties they exhibit. Electroanalysis employing carbon materials for biomolecules has been the focus of research because electrochemical methods provide the advantages of versatility and responsiveness in developing a sensor design [86].

Magnetic NPs with high contrast for MRIs have only shown their worth so far in an in vitro setting [87]. In the past, researchers have shown that nanoparticles coated with human serum albumin (HSA and IO/HSA NPs) prolong the half-lives of cross-linked medicinal compounds [88]. Tzameret et al. [88] injected IO/HSA NPs suprachoroid of a rat retinal model and monitored them in vivo using MRI to assess their long-term safety. Independently, Jaidev et al. [76] synthesised fluorescent iron oxide NPs and tested their viability for imaging RB cells. In order to prepare and stabilize the iron oxide NPs, oleic acid was used in the process. Nanoparticles of iron oxide coated with oleic acid were used to adsorb sulforhodamine B onto albumin. Studies using magnetic resonance imaging (MRI) have shown that the nanomaterials have a strong negative contrast to both healthy and cancerous cells, indicating their bioavailability and noncytotoxicity. So far, MRIs have mostly used iron oxide (IO) NPs. Issues with stability and toxicity may be mitigated by the coating process.

The Role of Nanoparticles in RB Therapy: RB1 mutations cause the most prevalent juvenile eye malignancy [89]. The lower socioeconomic status that characterizes developing countries also contributes to the delay in diagnosis which contributes to the decline in the survival rate of RB [90]. Proliferation and cancer are both stoked by mutations in tumour suppressor genes [91]. Enucleation is the only treatment option for RB [92]. Radiation treatment and chemotherapy have been associated to a number of side effects, including systemic toxicity, neutropenia, renal toxicity, hepatotoxicity and thrombocytopenia, [93–96]. There is additional research being done on external beam radiation treatment. Therefore, it is difficult to deliver drugs to the eye because the ocular tissues have their own set of defenses. And other nanoformulations for medication delivery are effective enough to get around these restrictions [97,98]. A number of NP types, including multi-functionalized NPs, lipid-based NPs, and metallic NPs, have been demonstrated to be useful in the treatment of RB [99,100]. Despite the challenges provided by the current eye care system, RB may be treated using multi-functionalized nanomaterials for ocular medication delivery, as shown in Figure1. However, NPs that are produced have the potential to encapsulate the therapeutic moiety and increase the retention duration [101]. Due to their biodegradable nature, polymeric NPs can be safely and precisely delivered intravitreally in RB. Table2 details the essential characteristics of nanocarriers used in the therapy of RB.

Table 2: Different nanocarriers features

Referenc

Nanocarrier	Features	e
Gold NPs	Photoacoustic, ultrasound, and magnetic resonance imaging were all enhanced when mesoporous Aunanocages (AuNCs) were mixed with 96 Fe ₃ O ₄ NPs in both in vivo and in vitro settings.	
SilverNPs	The cytotoxic efficiency of silver nanoparticles (AgNPs) was tested on RB cells using a fast technology based on natural sources of brown seaweed 97 Turbinariaornate.	
LipidNPs	Melphalan and miR-181 were co-delivered in lipid nanoparticles (LNPs) with a 93% encapsulation efficiency against RB, and the LNPs could be 98 switched on and off.	
Folic acid NPs	To combat RB, a chitosan NP (CNP) and doxorubicin (DOX) loading system 99 was developed and coupled with folic acid.	
Hyaluronic acid NPs	Electrostatic hyaluronic acid (HA) coatings were used to provide a hydrophilic, anionic surface for nanomedicines based on nonviral 100 polymeric gene DNA complexes, enhancing their intravitreal mobility.	
Galactose NPs	When comparing RB cells to healthy cells, lectins, which are sugar moieties, are significantly overexpressed in RB. Because of this, galactose may be used 101 as a target for effective effects.	
Melphalan NPs	Melphalan spillage was reduced and targeted distribution was achieved by 102 using the double-emulsion technique.	




Figure 1: Nanomaterials for ocular medication delivery to treat retinoblastoma.

Nanocarrier-Based Therapies with Multiple Mechanisms of Action Against RB:

Synthesizing multi-functionalized NPs for targeted action by attaching specific ligands allows for more precise delivery to the overexpressed tissues. These NPs set the bar in a wide variety of infectious illnesses and aggressive malignancies. Attaching many ligands to a nanocarrier system makes it more versatile for targeting intracellular pathogens in infectious disorders. Biomarkers such as galactose, hyaluronic acid, and folic acid (all seen in Figure 2) are overexpressed in malignancies, notably RB. In

order to target RB cells, multi-functionalized NPs have been synthesized and attached to such overexpressed ligands.




Figure 2: Multifunctional retinoblastoma nanoparticles. Poly-D,L-lactic-co-glycolic acid.

The Intravitreal Chemotherapy of RB Using Surface-Modified Melphalan Nanoparticles: A two-step procedure for the production of a formulation was established by Sims et al. [102] via the use of song and double-step emulsion. In the first stage of the procedure, poly-D, L-lactic-coglycolic acid nanoparticles (PLGA NPs) were produced by adding a number of different fluorescent coumarin 6 (C6) molecules followed by the evaporation of the solvent that was present in the emulsion. The procedure of encapsulating coumarin was improved by making a single emulsion of oil in water (o/w). The emulsion was produced in batches ranging in size from 100 mg to 200 mg, and the active component used was carboxyl-terminated PLGA. After letting C6 steep in dichloromethane (DCM) for a full 24 hours, we added a trace amount of PLGA at the end. After three hours of solvent evaporation, 5% PVA solution was added to the final PLGA/C6/DCM formulation and vortexed, sonicated, and solvent evaporated. Using the doubleemulsion procedure, the medication was then added to melphalan PLGA NPs. Double-emulsion decreased melphalan manufacturing waste. PLGA was dissolved in DCM overnight and melphalan in EDTA buffer for the double-emulsion procedure. The preformed PLGA/DCM mixture was then used to dissolve melphalan/EDTA, which was then stirred continuously. The resulting mixture was added drop by drop to the 5% PVA solution before being vortexed, sonicated, and considered a conjugate consisting of PLGA, DCM, melphalan, and PVA. In order to stop melphalan from leaking out of NPs during production, the final nanoparticles were toughened.

Functionalized nanocarriers with galactose: Improved and focused treatment against RB is in great demand, and one molecular approach that has shown promise is based on sugar moieties as ligands. Overexpressed relative to normal cells, lectins bind sugar moieties in RB. Therefore, targeting lectins that are overexpressed is an effective strategy. By using carbodiimide chemistry to connect galactose carboxyl and chitosan amino groups, a new sugar receptor-targeted delivery method for etoposide was established (ETP). To begin the synthesis process, poly (lactide-coglycolide) NPs (NPs) were prepared and ETP was displaced into them. **Nanocarriers with a Functionalization for Hyaluronic Acid (HA):** The CD44 receptor in cells gives hyaluronic acid its adaptability, biodegradability, shielding, mobility, and anticancer action. The Food and Drug Administration (FDA) has authorized this marine polymer. Retinal gene therapy was created and tested as a potential treatment for retinoblastoma in a previous study. Electrostatically coating nanomedicines with HA increased intravitreal mobility by creating an

anionic hydrophilic covering. We studied the size, surface charges, zeta potential, and complexation of HA polyplexes ranging in molecular weight from low to high. When there was a larger concentration of HA, there was a corresponding increase in the anionic potential by a factor of four. An ex-vivo model that utilized excised cow eyes and fluorescent single-particle tracking (FSPT) demonstrated that HA-coated polyplexes had enhanced mobility in intact vitreous humour and were able to successfully endocytose CD44 receptors. The model was carried out to show that HA-coated polyplexes were able to endocytose CD44 receptors. It was shown with the use of this model that HA-coated polyplexes had the ability to endocytose CD44 receptors. Because proving that HA-coated polyplexes are capable of endocytosing CD44 receptors was the objective of this model, the decision was made to carry out the experiment. **Multifunctional Nanocarriers with Folic Acid (FA):** By incorporating a targeting moiety into nanocarriers, we may increase their efficacy in the targeted killing of malignant cells, making them more effective than systemic chemotherapy. Targeted moieties allow for the precise placement of anticancer medicines [113]. Folate receptor is a common targeting molecule. Treating the condition with folic acid may cause selective NP absorption and cytotoxicity against cancer cells only due to the robust upregulation of folate receptors in RB cells. Chitosan nanoparticles (CNPs) containing dioxycorticoid (DOX) were synthesized by Parveen and Sahoo [3, 4]. After the NPs were created, the folic acid was attached to them. After ionic gelation is used to couple chitosan nanoparticles (CNPs) to dioxanone (DOX), CNP pellets may be separated with 18,000 rpm @ 4 C for 30 minutes. Following lyophilization, centrifugation at 3000 rpm, and storage at 4 C, CNPs were coupled with folic acid through a distilled water-based process. NMR and FTIR were used to analyze FA conjugation on CNPs (FTIR). DOX-CNPs were more cytotoxic to RB cells than pure DOX or unconjugated DOX using the MTT test (a colourimetric technique for measuring cell metabolic activity). Additional investigation into the function of DOX in Y-79 cell apoptosis indicated that FA-DOX-CNPs facilitated cell death by activating mitochondrial pathways and leading to the release of cytochrome c and caspases enzymes. As a result, it was determined that NPs that specifically target FA are a successful, long-term treatment for RB. Additionally, de Moraes Profirio and Pessine (2018) used a 22-factorial design to optimize the formulation and characterize utilizing all the optimal characterization methodologies required for the safe and targeted distribution of carboplatin. In the end, we determined that the mean size of the PDI was 0.20, the NPs was 178 nm, the ζ -potential was 46.0 mV, the encapsulation efficiency was 35.5%, and the yield of the NPs was 92%. For the treatment of RB using multi-functionalized NPs, scientists have created ligands based on sugar moieties and ligands based on polymers, as mentioned above. Lectins acted as sugar moieties. Compared to normal cells, RB has dramatically elevated levels of galactose and HA. As a result, lectins that are overexpressed provide a more effective manner of targeting than other ligands. PLGA was the most stable polymeric ligand. If polymeric and sugar moieties are joined and functionalized in nanosystems, we expect remarkable specificity and stability. **Nanoparticles of lipids (LNPs):** Pharmaceuticals, nutraceuticals, and personal care products are just some of the many applications for lipid nanoparticles (LNPs) that are a vital element of nanotechnology. Lipids are the source of a wide variety of healthful compounds, the bulk of which are hydrophobic. These beneficial chemicals include carotenes, carotenes, fatty acids, tocopherols, polyphenols, flavonoids, and preservatives. In order to maintain the consistency of the formulations, it is necessary for all of these lipids to be encased as colloidal dispersions inside a physiological medium of the oil-in-water (o/w) type. Recently, LNPs have been recognized as potentially useful therapeutic agents for a wide range of conditions, from the treatment of cancer and infectious diseases to the detoxification of toxic metals. When it comes to chemotherapy for RB, melphalan is the medicine of choice. In spite of this, there is always the chance of immunogenicity and the consequent destruction of healthy cells. The encapsulation was successful 93% of the time when Tabatabaei et al. (2019) developed hot swappable LNPs with a diameter of 171 nm for the purpose of co-delivering melphalan and miR-181. In spite of these constraints, the researchers were able to encapsulate the molecules of interest in their investigation with great success. In the course of the manufacturing procedure, some melphalan and ethanol in a proportion of 10% was added to the lipid mixture. This was done in order to make melphalan-loaded LNPs, also known as LNP/melphalan. This was done in order to treat cancer patients. After the ethanol

was evaporated, a thin lipid coating was formed on the LNPs. In order to rehydrate the LNPs, 5% dextrose was added to water, and the combination was heated to 40 degrees Celsius for 30 minutes. Following the determination of melphalan concentration, miR-181a was encapsulated. The fluorescence displacement experiment was used to infer the miR-181 encapsulation effectiveness. Formulated NPs have been evaluated using a variety of characterization methods, with findings favoring LNPs in terms of enhanced apoptotic gene expression, greatest absorption, and targeted death of RB cells. **Nanoparticles of Solid Lipids (SLNs):** SLNs are a highly adaptable kind of lipid-based nanocarriers technology that combine the benefits of emulsions, liposomes, and polymeric particles. SLNs are lipid droplets that have a crystalline and highly organized form, and they are produced by synthesizing liposome blends that incorporate bioactive chemicals into their lipid matrix. These blends are used to create SLNs. The movement of bioactive substances is controlled by the SLN lipid matrix's physical state. Therapeutic targeting, drug stability, and controlled drug release are only some of the benefits of SLNs. SLNs were created by Ahmad et al.

(2019) with the intention of making the targeted administration of etoposide more straightforward in the battle against RB. The SLNs were produced by using the ultrasonication and melt-emulsification processes, respectively, throughout the manufacturing process. We were able to investigate the relationship between response factors including particle size, surface shape, and entrapment efficiency because to the fact that the novel SLNs were optimised with the help of a Box-Behnken design that included three levels of factoring. Because of this, we were able to test the efficiency of entrapping particles of a wide range of sizes and shapes (EE). Dimensions, entrapment efficiency, surface areas, and in-vitro drug release were the criteria that were used to define the SLNs. The dimensions were the single most crucial factor to consider. In spite of the absence of any systemic effects, pharmacokinetic investigations were carried out on Wister rats following an intravitreal injection of the SLN formulation. In addition, the gamma scintigraphic method was used so that researchers could evaluate the amount of SLN that had been deposited in the ocular tissues of albino rabbits. In gamma scintigraphy, radioisotopes, also known as radiopharmaceuticals, are injected into a patient's veins with the intention of locating areas of the body that have undergone necrosis, inflammation, or destruction. Locating the parts of the body that have been compromised in some way is one way to achieve this goal. The toxicity and morphological changes following therapy were then evaluated using histological examinations. The findings, however, showed that the improved formulation had particle sizes of 239.43 nm, PDIs of 0.261 0.001, and EEs of 80.96% and 2.21%. The greatest benefit of this formulation was the prolonged drug release over a period of seven days after a single intravitreal injection. The gamma scintigraphy data backed with the claims that the medication was released slowly over the course of seven days. Histological analyses showed that the SLNs were not harmful since they did not cause any ill effects at the back of the eyes. Therefore, it is evident that etoposide-loaded SLNs are an effective and secure method of treating RB.

Nanoliposomes: Lipids self-assemble into liposomes when they come into contact with water due to interactions between the lipids' hydrophobic system and the water. Due to the lack of direct interaction between the two, lipids' hydrophobic system is unaffected when they come into indirect contact with water. (Figure 3) [50]. [Further citation is required] In order for liposomes, which consist of a lipid bilayer surrounding an aqueous core, to gain additional activity, ligands are often attached to the liposomes. Liposomes may then be used in a variety of applications. After then, liposomes may be better able to carry out the purpose for which they were designed. In order to investigate necrosis in RB cell lines in both in vitro and in vivo situations, researchers Zhao et al. (2020) created cisplatin nanoliposomes. In order to get a deeper comprehension of the procedure, this step was taken. After the cells had been cultivated and then treated with Annexin V and propidium iodide, one was able to identify what percentage of the Y-79 cells had gone through the process of apoptosis. This was done so that one could calculate how many of the Y-79 cells had died (PI). Research initiatives that employ flow cytofluoroscopic techniques to identify the presence of dead cells often call for the use of a double staining kit that contains both annexin V and PI. Propidium iodide, often known as PI, is a stain that is used to identify necrotic or late apoptotic cells. These cells may be identified by the loss of integrity of

both the plasma membrane and the nuclear membrane. DNA fragmentation is a hallmark of necrotic cells as well as those that have undergone late stages of apoptosis. Necrotic cells and cells that have reached a late stage in the process of apoptosis are the only types of cells that have the capacity to fragment. DNA fragmentation is a hallmark of necrotic cells as well as those that have undergone late stages of apoptosis. The Annexin V matching signal offers a way that is capable of detecting the movement of a cell in a manner that is very sensitive. In addition to using Western blotting to investigate the various expressions of Bcl-2 and Bax, we measured the level of caspase-3 in Y-79 cells to determine whether or not there was a change in the amount of inflammatory caspase-3. Our goal was to establish whether or not there was a change in the amount of caspase-3 that is involved in the inflammatory response. Our objective was to determine whether or not there was a shift in the total quantity of caspase-3, an enzyme that plays a role in the body's inflammatory response. The most important thing for us was to find out whether or not there was a shift in the total quantity of caspase-3. After using bald mice to establish a tumour model based on Y-79 cells, the bald mice themselves were randomly distributed among three groups, each of which had five individuals. The cancer model was then examined using nudized mice as subjects. Cisplatin was injected into the naked mice that were part of the control group, whereas the animals who were part of the other group got saline. This was done so that the replies of both groups could be compared and contrasted. Following the administration of the injections, the mice had their tumours surgically removed, and then the animals were prepared for eating by humans. Afterwards, the mice were used in research. An evaluation of the combined sizes and masses of the tumours was carried out after the completion of the surgical removal of the tumours. The assessment of apoptotic cells was performed with the assistance of an in-situ cell death test kit, and the DNA that was required for RT-PCR was extracted with the assistance of magnetic beads. Both of these procedures were carried out in-house. In comparison to the cisplatin solution group and the DMSO group, the cisplatin liposome group had higher levels of Bax protein expression, larger Y79 apoptotic rates, and caspase-3 activity. Additionally, the cisplatin liposome group had decreased tumour volume and weight (p 0.05).




Figure 3: Using lipid and polymeric nanocarriers to overcome the ocular barrier.

Nanoparticles (Metallic): Nonspecific dispersion of chemotherapeutic drugs throughout the entire body presents a significant obstacle in cancer therapy. Metallic NPs are very useful for cancer therapy. The uncommon cancer RB may also be efficiently treated with metallic NPs after active or passive targeting [49].

Nanoparticles (Silver: AgNPs): The green production, low cost, stability, and good optical features of AgNPs have made them a popular choice for application in cancer therapies. The cytotoxic activity of AgNPs against RB cells was reported by Remya et al., who used a fast approach to synthesize the particles from brown seaweed *Turbinaria ornata*. UV-visible spectroscopy revealed the existence of AgNPs, and characterisation by XRD, FTIR, HR-TEM, and TGA gave further information. Synthesized AgNPs were found to have a total phenolic content of 43 nm and a high scavenging activity. The RB Y-79 cell line was also shown to be dosedependently sensitive to the cytotoxicity of the produced AgNPs, with an IC₅₀ of 10.5 g/mL. AgNPs were shown to be effective in targeting and treating cancers of the eye, leading researchers to conclude that they are a potential anticancer drug.

Nanoparticles (Gold: AuNPs): Because of their huge surface areas, which make it possible for many different functional molecules to be adsorbed on their surfaces, gold nanoparticles (AuNPs) have been recruited for use in the efficacy of medicine. However, because of their toxicity, they are only useful in certain contexts. For this reason, a green synthesis process was designed for the production of gold nanoparticles (GNPs) from *Vitis vinifera* extracts. The synthesized GNPs were safe for use in living systems and did not cause any cell damage. Human double minute 2 (HDM2) functional protein cells were shown to have these NPs implicated in the mechanistic way of knocking it out. Because of its role in suppressing p53's tumor-fighting abilities, HDM2 is being studied as a potential cancer therapeutic. Cells containing HDM2 are eliminated because they are overexpressed in retinoblastoma and must be silenced. Performing a comprehensive biosafety assessment is a crucial part of characterizing multifunctional NPs. Multifunctional magnetic AuNCs-Fe₃O₄/MDP/PFP nanocarriers improved both photoacoustic imaging and magnetic resonance, the study's authors found. After entering tumours in a targeted fashion, these nanocarriers aggregate there thanks to a magnetic field, where they then undergo a phase change and release MDP when exposed to radiation. Released MDP stimulated dendritic cell maturation and activation, leading to improved tumour cell recognition and clearance and promising new therapeutic outcomes against RB [79]. Metallic nanoparticles (silver and gold) have been produced by scientists to reduce RB malignancy; nevertheless, these nanoparticles are very hazardous. In our opinion, there is a possibility that the environmentally friendly production of metallic nanoparticles might be encouraged in order to achieve anticancer effectiveness without




Figure 4: By altering the conjugated (AuNCs-Fe₃O₄) nanoparticle system, AuNCs-Fe₃O₄/MDP/PFP was developed.

Conclusions: In a number of different settings, it has been shown that NP-mediated anticancer medication delivery is more effective than conventional anticancer therapy. [Further citation is required] These include a lessening of the medicine's toxicity, an increase in the specificity with which it binds to the ligand, an enhancement in the medicine's ability to regulate cytotoxicity, and reduce overall expenses. It has been shown that the use of biocompatible polymers is advantageous in the treatment of RB, both in terms of overcoming obstacles and avoiding the destruction of healthy cells. These include ligands and metallic NPs that are made by environmentally friendly synthesis, as well as bioactive and nontoxic lipid nanoparticles that are formed from herbal flavonoid components. Both the diagnosis and treatment of RB have seen significant advancements attributable, in large part, to two relatively new paths in cancer therapy: multi-functionalization and immunogenicity. These directions have allowed for significant improvement. Because of the recent advances that have been made in multifunctionalization, it is now possible to explore these new techniques. These advancements have made it possible. As a direct result of the revolutionary progress made in the field of nanomedicine in the detection of cancer, researchers are currently evaluating cell- and tissuespecific nanosystems in an effort to satisfy the

stringent criteria of ophthalmic chemotherapy and diagnostics. This effort is a direct result of the revolutionary progress made in the field of nanomedicine. This is a result of ground-breaking developments that have been achieved in the area of nanomedicine with regard to the diagnosis of cancer. In addition to providing a comprehensive grasp of the imaging and distribution of ocular drugs within the scope of this research, we also provided an awareness of the conceptual requirements of the design. It is required to construct combinatory techniques that are appropriate for a variety of design parameters in order to reach the final goal of creating "smart nanosystems" to combat very deadly intraocular tumours. This will allow for the achievement of the ultimate target. This is necessary in order to accomplish the goal at hand. Because of this, it will be able to achieve the ultimate goal. [Cause and effect] When it come to the management of RB, one of the challenges that must be overcome is the insufficiency of therapeutic therapy. This difficulty comes as a result of the one-of-a-kind and intricate physiological and anatomical impediments that exist in the region of the eye that is affected by the condition. Because of these challenges, which are made even more challenging to overcome thanks to the pharmaceutical leakage and nontargeted distribution, respectively, the problem is made to be much tougher to solve. Despite this, it was still feasible for multi-functionalized ligand-based nanocarriers to retain their effectiveness as therapeutic agents. This was shown in a study published in Nature Nanotechnology.

References

1. Fabian, I.D.; Onadim, Z.; Karaa, E.; Duncan, C.; Chowdhury, T.; Scheimberg, I.; Ohnuma, S.-I.; Reddy, M.A.; Sagoo, M.S. The management of retinoblastoma. *Oncogene* **2018**, *37*, 1551–1560. [[CrossRef](#)] [[PubMed](#)]
2. Baranei, M.; Taheri, R.A.; Tirgar, M.; Saeidi, A.; Oroojalian, F.; Uzun, L.; Asefnejad, A.; Wurm, F.R.; Goodarzi, V. Anticancer effect of green tea extract (GTE)-Loaded pH-responsive niosome Coated with PEG against different cell lines. *Mater. Today Commun.* **2020**, *26*, 101751. [[CrossRef](#)]
3. Barani, M.; Bilal, M.; Rahdar, A.; Arshad, R.; Kumar, A.; Hamishekar, H.; Kyzas, G.Z. Nanodiagnosis and nanotreatment of colorectal cancer: An overview. *J. Nanoparticle Res.* **2021**, *23*, 1–25. [[CrossRef](#)]
4. Barani, M.; Bilal, M.; Sabir, F.; Rahdar, A.; Kyzas, G.Z. Nanotechnology in ovarian cancer: Diagnosis and treatment. *Life Sci.* **2020**, *266*, 118914.
5. Barani, M.; Mirzaei, M.; Mahani, M.T.; Nematollahi, M.H. Lawsone-loaded Niosome and its Antitumor Activity in MCF-7 Breast Cancer Cell Line: A Nano-herbal Treatment for Cancer. *DARU J. Pharm. Sci.* **2018**, 1–7. [[CrossRef](#)]
6. Barani, M.; Mirzaei, M.; Torkzadeh-Mahani, M.; Adeli-Sardou, M. Evaluation of carumloaded niosomes on breast cancer cells: Physicochemical properties, in vitro cytotoxicity, flow cytometric, DNA fragmentation and cell migration assay. *Sci. Rep.* **2019**, *9*, 1–10. [[CrossRef](#)]
7. Chen, F.; Si, P.; de la Zerda, A.; Jokerst, J.V.; Myung, D. Gold nanoparticles to enhance ophthalmic imaging. *Biomater. Sci.* **2021**, *9*, 367–390. [[CrossRef](#)]
8. Barani, M.; Mirzaei, M.; Torkzadeh-Mahani, M.; Lohrasbi-Nejad, A.; Nematollahi, M.H. A new formulation of hydrophobin-coated niosome as a drug carrier to cancer cells. *Mater. Sci. Eng. C* **2020**, *113*, 110975. [[CrossRef](#)]
9. Barani, M.; Mukhtar, M.; Rahdar, A.; Sargazi, G.; Thysiadou, A.; Kyzas, G.Z. Progress in the Application of Nanoparticles and Graphene as Drug Carriers and on the Diagnosis of Brain Infections. *Molecules* **2021**, *26*, 186. [[CrossRef](#)] [[PubMed](#)]
10. Barani, M.; Nematollahi, M.H.; Zaboli, M.; Mirzaei, M.; Torkzadeh-Mahani, M.; Pardakhty, A.; Karam, G.A. In silico and in vitro study of magnetic niosomes for gene delivery: The effect of ergosterol and cholesterol. *Mater. Sci. Eng. C* **2019**, *94*, 234–246. [[CrossRef](#)]
11. Barani, M.; Sabir, F.; Rahdar, A.; Arshad, R.; Kyzas, G.Z. Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates. *Nanomaterials* **2020**, *10*, 1696. [[CrossRef](#)] [[PubMed](#)]
12. Barani, M.; Torkzadeh-Mahani, M.; Mirzaei, M.; Nematollahi, M.H. Comprehensive evaluation of gene expression in negative and positive trigger-based targeting niosomes in HEK-293 cell line. *Iran. J. Pharm. Res. IJPR* **2020**, *19*, 166.
13. Bilal, M.; Barani, M.; Sabir, F.; Rahdar, A.; Kyzas, G.Z. Nanomaterials for the treatment and diagnosis of Alzheimer's disease: An overview. *NanoImpact* **2020**, 100251. [[CrossRef](#)]
14. Das, S.S.; Bharadwaj, P.; Bilal, M.; Barani, M.; Rahdar, A.; Taboada, P.; Bungau, S.; Kyzas, G.Z. Stimuli-responsive polymeric nanocarriers for drug delivery, imaging, and theragnosis. *Polymers* **2020**, *12*, 1397. [[CrossRef](#)]
15. Davarpanah, F.; Yazdi, A.K.; Barani, M.; Mirzaei, M.; Torkzadeh-Mahani, M. Magnetic delivery of antitumor carboplatin by using PEGylated-Niosomes. *DARU J. Pharm. Sci.* **2018**, *26*, 57–64. [[CrossRef](#)]
16. Ebrahimi, A.K.; Barani, M.; Sheikhsheoiaie, I. Fabrication of a new superparamagnetic metalorganic framework with core-shell nanocomposite structures: Characterization, biocompatibility, and drug

- release study. *Mater. Sci. Eng. C* **2018**, 92, 349–355. [[CrossRef](#)] [[PubMed](#)] 17. Ghazy, E.; Kumar, A.; Barani, M.; Kaur, I.; Rahdar, A.; Behl, T. Scrutinizing the Therapeutic and Diagnostic Potential of Nanotechnology in Thyroid Cancer: Edifying drug targeting by nano-oncotherapeutics. *J. Drug Deliv. Sci. Technol.* **2020**, 102221. [[CrossRef](#)]
18. Ghazy, E.; Rahdar, A.; Barani, M.; Kyzas, G.Z. Nanomaterials for Parkinson disease: Recent progress. *J. Mol. Struct.* **2020**, 129698.
19. Hajizadeh, M.R.; Maleki, H.; Barani, M.; Fahmidehkar, M.A.; Mahmoodi, M.; TorkzadehMahani, M. In vitro cytotoxicity assay of D-limonene niosomes: An efficient nano-carrier for enhancing solubility of plant-extracted agents. *Res. Pharm. Sci.* **2019**, 14, 448.
20. Hajizadeh, M.R.; Parvaz, N.; Barani, M.; Khoshdel, A.; Fahmidehkar, M.A.; Mahmoodi, M.; Torkzadeh-Mahani, M. Diosgenin-loaded niosome as an effective phytochemical nanocarrier: Physicochemical characterization, loading efficiency, and cytotoxicity assay. *DARU J. Pharm. Sci.* **2019**, 27, 329–339. [[CrossRef](#)]
21. Zahin, N.; Anwar, R.; Tewari, D.; Kabir, M.T.; Sajid, A.; Mathew, B.; Uddin, M.S.; Aleya, L.; Abdel-Daim, M.M. Nanoparticles and its biomedical applications in health and diseases: Special focus on drug delivery. *Environ. Sci. Pollut. Res.* **2019**, 1–18. [[CrossRef](#)]
22. Mukhtar, M.; Bilal, M.; Rahdar, A.; Barani, M.; Arshad, R.; Behl, T.; Brisc, C.; Banica, F.; Bungau, S. Nanomaterials for Diagnosis and Treatment of Brain Cancer: Recent Updates. *Chemosensors* **2020**, 8, 117. [[CrossRef](#)]
23. Nikazar, S.; Barani, M.; Rahdar, A.; Zoghi, M.; Kyzas, G.Z. Photo-and Magneto-thermally Responsive Nanomaterials for Therapy, Controlled Drug Delivery and Imaging Applications. *ChemistrySelect* **2020**, 5, 12590–12609. [[CrossRef](#)]
24. Rahdar, A.; Hajinezhad, M.R.; Nasri, S.; Beyzaei, H.; Barani, M.; Trant, J.F. The synthesis of methotrexate-loaded F127 microemulsions and their in vivo toxicity in a rat model. *J. Mol. Liquids* **2020**, 313, 113449. [[CrossRef](#)]
25. Rahdar, A.; Hajinezhad, M.R.; Sargazi, S.; Barani, M.; Bilal, M.; Kyzas, G.Z. Deferasirox-loaded pluronic nanomicelles: Synthesis, characterization, in vitro and in vivo studies. *J. Mol. Liquids* **2021**, 323, 114605. [[CrossRef](#)]
26. Rahdar, A.; Hajinezhad, M.R.; Sargazi, S.; Bilal, M.; Barani, M.; Karimi, P.; Kyzas, G.Z. Biochemical effects of deferasirox and deferasirox-loaded nanomicelles in iron-intoxicated rats. *Life Sci.* **2021**, 119146. [[CrossRef](#)]
27. Rahdar, A.; Taboada, P.; Hajinezhad, M.R.; Barani, M.; Beyzaei, H. Effect of tocopherol on the properties of Pluronic F127 microemulsions: Physico-chemical characterization and in vivo toxicity. *J. Mol. Liquids* **2019**, 277, 624–630. [[CrossRef](#)]
28. Barani, M.; Mukhtar, M.; Rahdar, A.; Sargazi, S.; Pandey, S.; Kang, M. Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma. *Biosensors* **2021**, 11, 55. [[CrossRef](#)]
29. Torkzadeh-Mahani, M.; Zaboli, M.; Barani, M.; Torkzadeh-Mahani, M. A combined theoretical and experimental study to improve the thermal stability of recombinant D-lactate dehydrogenase immobilized on a novel superparamagnetic Fe₃O₄NPs@ metal-organic framework. *Appl. Organomet. Chem.* **2020**, 34, e5581. [[CrossRef](#)]
30. Mattosinho, C.C.D.S.; Moura, A.T.M.; Oigman, G.; Ferman, S.E.; Grigorovski, N. Time to diagnosis of retinoblastoma in Latin America: A systematic review. *Pediatric Hematol. Oncol.* **2019**,

- 36, 55–72. [[CrossRef](#)] [[PubMed](#)]
31. Giacalone, M.; Mastrangelo, G.; Parri, N. Point-of-care ultrasound diagnosis of retinoblastoma in the emergency department. *Pediatric Emerg. Care* **2018**, *34*, 599–601. [[CrossRef](#)]
32. Khoo, S.A.; Ong, G.Y.-K. Use of Ocular Point-of-Care Ultrasound in a Difficult Pediatric Examination: A Case Report of an Emergency Department Diagnosis of Retinoblastoma. *J. Emerg. Med.* **2020**, *58*, 632–635. [[CrossRef](#)]
33. Li, Z.; Guo, J.; Xu, X.; Wang, Y.; Mukherji, S.K.; Xian, J. Diagnosis of Postlaminar optic nerve invasion in retinoblastoma with MRI features. *J. Magn. Reson. Imaging* **2020**, *51*, 1045–1052. [[CrossRef](#)]
34. Neupane, R.; Gaudana, R.; Boddu, S.H. Imaging techniques in the diagnosis and management of ocular tumors: Prospects and challenges. *AAPS J.* **2018**, *20*, 1–12. [[CrossRef](#)]
35. Sun, J.; Xi, H.-Y.; Shao, Q.; Liu, Q.-H. Biomarkers in retinoblastoma. *Int. J. Ophthalmol.* **2020**, *13*, 325. [[CrossRef](#)]
36. Golabchi, K.; Soleimani-Jelodar, R.; Aghadoost, N.; Momeni, F.; Moridikia, A.; Nahand, J.S.; Masoudifar, A.; Razmjoo, H.; Mirzaei, H. MicroRNAs in retinoblastoma: Potential diagnostic and therapeutic biomarkers. *J. Cell. Physiol.* **2018**, *233*, 3016–3023. [[CrossRef](#)] [[PubMed](#)]
37. Chen, X.-J.; Zhang, X.-Q.; Liu, Q.; Zhang, J.; Zhou, G. Nanotechnology: A promising method for oral cancer detection and diagnosis. *J. Nanobiotechnol.* **2018**, *16*, 1–17. [[CrossRef](#)]
38. Sabir, F.; Barani, M.; Rahdar, A.; Bilal, M.; Zafar, N.M.; Bungau, S.; Kyzas, G.Z. How to Face Skin Cancer with Nanomaterials: A Review. *Biointerface Res. Appl. Chem.* **2021**, *11*, 11931–11955.
39. Zhang, Y.; Li, M.; Gao, X.; Chen, Y.; Liu, T. Nanotechnology in cancer diagnosis: Progress, challenges and opportunities. *J. Hematol. Oncol.* **2019**, *12*, 1–13. [[CrossRef](#)]
40. Cruz-Alonso, M.; Fernandez, B.; Álvarez, L.; González-Iglesias, H.; Traub, H.; Jakubowski, N.; Pereiro, R. Bioimaging of metallothioneins in ocular tissue sections by laser ablation-ICP-MS using bioconjugated gold nanoclusters as specific tags. *Microchim. Acta* **2018**, *185*, 1–9. [[CrossRef](#)]
41. Toda, M.; Yukawa, H.; Yamada, J.; Ueno, M.; Kinoshita, S.; Baba, Y.; Hamuro, J. In vivo fluorescence visualization of anterior chamber injected human corneal endothelial cells labeled with quantum dots. *Investig. Ophthalmol. Vis. Sci.* **2019**, *60*, 4008–4020. [[CrossRef](#)]
42. Wang, M.; Yang, Q.; Li, M.; Zou, H.; Wang, Z.; Ran, H.; Zheng, Y.; Jian, J.; Zhou, Y.; Luo, Y.; et al. Multifunctional Nanoparticles for Multimodal Imaging-Guided Low-Intensity Focused Ultrasound/Immunosynergistic Retinoblastoma Therapy. *ACS Appl. Mater. Interfaces* **2020**, *12*, 5642–5657. [[CrossRef](#)]
43. Garner, I.; Vichare, R.; Paulson, R.; Appavu, R.; Panguluri, S.K.; Tzekov, R.; Sahiner, N.; Ayyala, R.; Biswal, M.R. Carbon dots fabrication: Ocular imaging and therapeutic potential. *Front. Bioeng. Biotechnol.* **2020**, *8*, 1139. [[CrossRef](#)]
44. Sarwat, S.; Stapleton, F.; Willcox, M.; Roy, M. Quantum Dots in Ophthalmology: A Literature Review. *Curr. Eye Res.* **2019**, *44*, 1037–1046. [[CrossRef](#)] [[PubMed](#)]
45. Mahan, M.M.; Doiron, A.L. Gold nanoparticles as X-ray, CT, and multimodal imaging contrast agents: Formulation, targeting, and methodology. *J. Nanomater.* **2018**, *2018*. [[CrossRef](#)]
46. Moradi, S.; Mokhtari-Dizaji, M.; Ghassemi, F.; Sheibani, S.; Asadi Amoli, F. Increasing the efficiency of the retinoblastoma brachytherapy protocol with ultrasonic hyperthermia and gold nanoparticles: A rabbit model. *Int. J. Radiat. Biol.* **2020**, *96*, 1614–1627. [[CrossRef](#)]

- [PubMed] 47. Mohajeri, M.; Behnam, B.; Sahebkar, A. Biomedical applications of carbon nanomaterials: Drug and gene delivery potentials. *J. Cell. Physiol.* **2019**, *234*, 298–319. [CrossRef] [PubMed]
48. Power, A.C.; Gorey, B.; Chandra, S.; Chapman, J. Carbon nanomaterials and their application to electrochemical sensors: A review. *Nanotechnol. Rev.* **2018**, *7*, 19–41. [CrossRef]
49. Farzin, A.; Etesami, S.A.; Quint, J.; Memic, A.; Tamayol, A. Magnetic nanoparticles in cancer therapy and diagnosis. *Adv. Healthc. Mater.* **2020**, *9*, 1901058. [CrossRef]
50. Tzameret, A.; Ketter-Katz, H.; Edelshtain, V.; Sher, I.; Corem-Salkmon, E.; Levy, I.; Last, D.; Guez, D.; Mardor, Y.; Margel, S. In vivo MRI assessment of bioactive magnetic iron oxide/human serum albumin nanoparticle delivery into the posterior segment of the eye in a rat model of retinal degeneration. *J. Nanobiotechnol.* **2019**, *17*, 1–11. [CrossRef]
51. Jain, M.; Rojanaporn, D.; Chawla, B.; Sundar, G.; Gopal, L.; Khetan, V. Retinoblastoma in Asia. *Eye* **2019**, *33*, 87–96. [CrossRef] [PubMed]
52. Mehyar, M.; Mosallam, M.; Tbakhi, A.; Saab, A.; Sultan, I.; Deebajah, R.; Jaradat, I.; AlJabari, R.; Mohammad, M.; AlNawaiseh, I. Impact of RB1 gene mutation type in retinoblastoma patients on clinical presentation and management outcome. *Hematol. Oncol. Stem Cell Ther.* **2020**, *13*, 152–159. [CrossRef]
53. Cocarta, A.-I.; Hobzova, R.; Sirc, J.; Cerna, T.; Hrabeta, J.; Svojgr, K.; Pochop, P.; Kodetova, M.; Jedelska, J.; Bakowsky, U. Hydrogel implants for transscleral drug delivery for retinoblastoma treatment. *Mater. Sci. Eng. C* **2019**, *103*, 109799. [CrossRef] [PubMed]
54. Xue, K.; Ren, H.; Meng, F.; Zhang, R.; Qian, J. Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients. *BMC Ophthalmol.* **2019**, *19*, 1–8. [CrossRef]
55. Kleinerman, R.A.; Tucker, M.A.; Sigel, B.S.; Abramson, D.H.; Seddon, J.M.; Morton, L.M. Patterns of cause-specific mortality among 2053 survivors of retinoblastoma, 1914–2016. *JNCI J. Natl. Cancer Inst.* **2019**, *111*, 961–969. [CrossRef] [PubMed]
56. Dimaras, H.; Corson, T.W. Retinoblastoma, the visible CNS tumor: A review. *J. Neurosci. Res.* **2019**, *97*, 29–44. [CrossRef] [PubMed]
57. Raguraman, R.; Parameswaran, S.; Kanwar, J.R.; Khetan, V.; Rishi, P.; Kanwar, R.K.; Krishnakumar, S. Evidence of tumour microenvironment and stromal cellular components in retinoblastoma. *Ocular Oncol. Pathol.* **2019**, *5*, 85–93. [CrossRef]
58. Gao, R.; Mitra, R.N.; Zheng, M.; Wang, K.; Dahringer, J.C.; Han, Z. Developing NanoceriaBased pH-Dependent Cancer-Directed Drug Delivery System for Retinoblastoma. *Adv. Funct. Mater.* **2018**, *28*, 1806248. [CrossRef] [PubMed]
59. Sims, L.B.; Tyo, K.M.; Stocke, S.; Mahmoud, M.Y.; Ramasubramanian, A.; SteinbachRankins, J.M. Surface-Modified Melphalan Nanoparticles for Intravitreal Chemotherapy of Retinoblastoma. *Investig. Ophthalmol. Vis. Sci.* **2019**, *60*, 1696–1705. [CrossRef] [PubMed]
60. Godse, R.; Rathod, M.; De, A.; Shinde, U. Intravitreal galactose conjugated polymeric nanoparticles of etoposide for retinoblastoma. *J. Drug Deliv. Sci. Technol.* **2021**, *61*, 102259. [CrossRef]
61. Correia, A.R.; Sampaio, I.; Comparetti, E.J.; Vieira, N.C.S.; Zucolotto, V. Optimized PAH/Folic acid layer-by-layer films as an electrochemical biosensor for the detection of folate receptors. *Bioelectrochemistry* **2020**, *137*, 107685. [CrossRef]

62. Tabatabaei, S.N.; Derbali, R.M.; Yang, C.; Superstein, R.; Hamel, P.; Chain, J.L.; Hardy, P. Co-delivery of miR-181a and melphalan by lipid nanoparticles for treatment of seeded retinoblastoma. *J. Control. Release* **2019**, *298*, 177–185. [[CrossRef](#)]
63. Chugh, H.; Sood, D.; Chandra, I.; Tomar, V.; Dhawan, G.; Chandra, R. Role of gold and silver nanoparticles in cancer nano- medicine. *Artif. Cells Nanomed. Biotechnol.* **2018**, *46*, 1210–1220. [[CrossRef](#)]
64. Chen, Y.; Sun, S.; Li, C.; Hao, Y. Rosiglitazone Gold Nanoparticles Attenuate the Development of Retinoblastoma by Repressing the PI3K/Akt Pathway. *Nanosci. Nanotechnol. Lett.* **2020**, *12*, 820–826.
65. Guo, X.; Zhuang, Q.; Ji, T.; Zhang, Y.; Li, C.; Wang, Y.; Li, H.; Jia, H.; Liu, Y.; Du, L. Multifunctionalized chitosan nanoparticles for enhanced chemotherapy in lung cancer. *Carbohydr. Polym.* **2018**, *195*, 311–320. [[CrossRef](#)]
66. Song, Y.; Tang, C.; Yin, C. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells. *Biomaterials* **2018**, *185*, 117–132. [[CrossRef](#)]
67. De Moraes Profirio, D.; Pessine, F.B.T. Formulation of functionalized PLGA nanoparticles with folic acid-conjugated chitosan for carboplatin encapsulation. *Eur. Polym. J.* **2018**, *108*, 311–321. [[CrossRef](#)]
68. Ramishetti, S.; Hazan-Halevy, I.; Palakuri, R.; Chatterjee, S.; Naidu Gonna, S.; Dammes, N.; Freilich, I.; Kolik Shmuel, L.; Danino, D.; Peer, D. A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes. *Adv. Mater.* **2020**, *32*, 1906128. [[CrossRef](#)] [[PubMed](#)]
69. Patel, S.; Ashwanikumar, N.; Robinson, E.; Xia, Y.; Mihai, C.; Griffith, J.P.; Hou, S.; Esposito, A.A.; Ketova, T.; Welsher, K. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. *Nat. Commun.* **2020**, *11*, 1–13. [[CrossRef](#)] [[PubMed](#)]
70. Yu, X.; Dai, Y.; Zhao, Y.; Qi, S.; Liu, L.; Lu, L.; Luo, Q.; Zhang, Z. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response. *Nat. Commun.* **2020**, *11*, 1–14. [[CrossRef](#)]
71. Paliwal, R.; Paliwal, S.R.; Kenwat, R.; Kurmi, B.D.; Sahu, M.K. Solid lipid nanoparticles: A review on recent perspectives and patents. *Expert Opin. Ther. Pat.* **2020**, *30*, 179–194. [[CrossRef](#)]
72. Ban, C.; Jo, M.; Park, Y.H.; Kim, J.H.; Han, J.Y.; Lee, K.W.; Kweon, D.-H.; Choi, Y.J. Enhancing the oral bioavailability of curcumin using solid lipid nanoparticles. *Food Chem.* **2020**, *302*, 125328. [[CrossRef](#)] [[PubMed](#)]
73. Ahmad, I.; Pandit, J.; Sultana, Y.; Mishra, A.K.; Hazari, P.P.; Aqil, M. Optimization by design of etoposide loaded solid lipid nanoparticles for ocular delivery: Characterization, pharmacokinetic and deposition study. *Mater. Sci. Eng. C* **2019**, *100*, 959–970. [[CrossRef](#)]
74. Crommelin, D.J.; van Hoogevest, P.; Storm, G. The role of liposomes in clinical nanomedicine development. What now? Now what? *J. Control. Release* **2020**, *318*, 256–263. [[CrossRef](#)] [[PubMed](#)]
75. Tai, K.; Rappolt, M.; Mao, L.; Gao, Y.; Li, X.; Yuan, F. The stabilization and release performances of curcumin-loaded liposomes coated by high and low molecular weight chitosan. *Food Hydrocoll.* **2020**, *99*, 105355. [[CrossRef](#)]
76. Zhao, L.; Wang, F.; Fan, W. Cisplatin Nano-Liposomes Promoting Apoptosis of Retinoblastoma Cells Both In Vivo and In Vitro.

Nanosci. Nanotechnol. Lett. **2020**, *12*, 536–542. [[CrossRef](#)]

77. Sharma, A.; Goyal, A.K.; Rath, G. Recent advances in metal nanoparticles in cancer therapy. *J. Drug Target.* **2018**, *26*, 617–632. [[CrossRef](#)]

78. Pallares, R.M.; Thanh, N.T.K.; Su, X. Sensing of circulating cancer biomarkers with metal nanoparticles. *Nanoscale* **2019**, *11*, 22152–22171. [[CrossRef](#)]

79. Arshad, R.; Pal, K.; Sabir, F.; Rahdar, A.; Bilal, M.; Shahnaz, G.; Kyzas, G.Z. A review of the nanomaterials use for the diagnosis and therapy of salmonella typhi. *J. Mol. Struct.* **2021**, *1230*, 129928. [[CrossRef](#)]

80. Remya, R.; Rajasree, S.R.; Suman, T.; Aranganathan, L.; Gayathri, S.; Gobalakrishnan, M.; Karthih, M. Laminarin based AgNPs using brown seaweed *Turbinaria ornata* and its induction of apoptosis in human retinoblastoma Y79 cancer cell lines. *Mater. Res. Express* **2018**, *5*, 035403.

[[CrossRef](#)]

81. Bromma, K.; Chithrani, D.B. Advances in Gold Nanoparticle-Based Combined Cancer Therapy. *Nanomaterials* **2020**, *10*, 1671. [[CrossRef](#)]

82. Kumar, P.; Saini, M.; Dehiya, B.S.; Sindhu, A.; Kumar, V.; Kumar, R.; Lamberti, L.; Pruncu, C.I.; Thakur, R. Comprehensive survey on nanobiomaterials for bone tissue engineering applications.

Nanomaterials **2020**, *10*, 2019. [[CrossRef](#)]

83. Arshad, R.; Sohail, M.F.; Sarwar, H.S.; Saeed, H.; Ali, I.; Akhtar, S.; Hussain, S.Z.; Afzal, I.; Jahan, S.; Shahnaz, G. ZnO-NPs embedded biodegradable thiolated bandage for postoperative surgical site infection: In vitro and in vivo evaluation. *PLoS ONE* **2019**, *14*, e0217079. [[CrossRef](#)]

[[PubMed](#)]

84. Pandey, S. (2022). Advance Nanomaterials for Biosensors. *Biosensors*, *12*(4), 219.

85. Mandal, M., Banerjee, I., & Mandal, M. (2022). Nanoparticle-mediated Gene Therapy as a Novel Strategy for the Treatment of Retinoblastoma. *Colloids and Surfaces B: Biointerfaces*, 112899.

86. Farhat, W., Yeung, V., Ross, A., Kahale, F., Boychev, N., Kuang, L., ... & Ciolino, J. (2022). Advances in biomaterials for the treatment of retinoblastoma. *Biomaterials Science*.

87. Mohseni, M., Shojaei, Y., Naseripour, M., Delavar, F., Mirzaei, M., & Mehraei, B. (2022). Lauric acid-grafted biopolymeric nanoparticles for efficient Melphalan delivery across the corneal layers for retinoblastoma: ex vivo and in vivo permeation study. *Advances in Natural Sciences:*

Nanoscience and Nanotechnology, *13*(3), 035005.

88. Ghaleh, H. E. G., Shahriary, A., Izadi, M., & Farzanehpour, M. (2022). Advances in early diagnosis of cervical cancer based on biosensors. *Biotechnology and Bioengineering*, *119*(9), 23052312.

89. Yan, L., Shi, F., Zhang, J., Niu, Y., Huang, L., Huang, Y., & Sun, W. (2022). Electrochemical DNA Biosensor Based on Platinum-gold Bimetal Decorated Graphene Modified Electrode for the Detection of *Vibrio parahaemolyticus* Specific *tlh* Gene Sequence. *Current Analytical Chemistry*, *18*(7), 781-789.

90. Kumar, I., Nayak, R., Chaudhary, L. B., Pandey, V. N., Mishra, S. K., Singh, N. K., ... & Naik, R. M. (2022). Fabrication of α -Fe₂O₃ Nanostructures: Synthesis, Characterization, and Their Promising Application in the Treatment of Carcinoma A549 Lung Cancer Cells. *ACS omega*, *7*(25), 21882-21890.

91. Li, Y., Zhu, Z., Lv, Z., Wang, Z., & Chen, Y. (2022). Adsorption characteristics of bovine serum albumin onto α -Fe₂O₃ nanoparticles prepared via the alcohol solution combustion process of ferric nitrate. *Materials Research Express*.
92. Wang, F., Li, P., Chu, H. C., & Lo, P. K. (2022). Nucleic acids and their analogues for biomedical applications. *Biosensors*, 12(2), 93.
93. Ghaznavi, H., Hajinezhad, M. R., Shirvaliloo, M., Shahraki, S., Shahraki, K., Saravani, R., ... & Sargazi, S. (2022). Effects of folate-conjugated Fe₂O₃@ Au core-shell nanoparticles on oxidative stress markers, DNA damage, and histopathological characteristics: evidence from in vitro and in vivo studies. *Medical Oncology*, 39(9), 1-14.
94. Herbin, H. B., Aravind, M., Amalanathan, M., Mary, M., Lenin, M. M., Parvathiraja, C., ... & Islam, M. A. (2022). Synthesis of Silver Nanoparticles Using Syzygium malaccense Fruit Extract and Evaluation of Their Catalytic Activity and Antibacterial Properties. *Journal of Inorganic and Organometallic Polymers and Materials*, 32(3), 1103-1115.
95. Gourani, P., Sedeh, A. B., Zareyi, H., Shirvaliloo, M., Sheervalilou, R., & Ghaznavi, H. (2022). Gold Nanoparticle Effects on the Hounsfield Unit of Computed Tomography in Hepatocellular Carcinoma: Systematic Review.
96. Haghghat, M., Alijani, H. Q., Ghasemi, M., Khosravi, S., Borhani, F., Sharifi, F., ... & Khatami, M. (2022). Cytotoxicity properties of plant-mediated synthesized K-doped ZnO nanostructures. *Bioprocess and Biosystems Engineering*, 45(1), 97-105.
97. Ye, R. H., Chen, J. Y., Huang, D. H., Wang, Y. J., & Chen, S. (2022). Electrochemical Sensor Based on Glassy-Carbon Electrode Modified with Dual-Ligand EC-MOFs Supported on rGO for BPA. *Biosensors*, 12(6), 367.
98. Yin, S., Wang, J., Zhu, Y., Song, L., Wu, T., Zhang, Z., ... & Chen, G. (2022). A Novel Uric Acid Biosensor Based on Regular Prussian Blue Nanocrystal/Upright Graphene Oxide Array Nanocomposites. *Current Analytical Chemistry*, 18(7), 809-817.
99. Nazaripour, E., Mosazadeh, F., Rahimi, S. S., Alijani, H. Q., Isaei, E., Borhani, F., ... & Khatami, M. (2022). Ferromagnetic nickel (II) oxide (NiO) nanoparticles: biosynthesis, characterization and their antibacterial activities. *Rendiconti Lincei. Scienze Fisiche e Naturali*, 33(1), 127-134.
100. Mehta, A., Sen, G., & Pandey, J. P. (2022). Microwave-assisted cationization of Gum ghatti by grafting with diallyldimethylammonium chloride (DADMAC) and its applications as nano scavenger. *Industrial Crops and Products*, 179, 114637.
101. Subaihi, A., & Naglah, A. M. (2022). Facile synthesis and characterization of Fe₂O₃ nanoparticles using L-lysine and L-serine for efficient photocatalytic degradation of methylene blue dye. *Arabian Journal of Chemistry*, 15(2), 103613.
102. Mahadik, N., Bhattacharya, D., Padmanabhan, A., Sakhare, K., Narayan, K. P., & Banerjee, R. (2022). Targeting steroid hormone receptors for anti-cancer therapy—A review on small molecules and nanotherapeutic approaches. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, 14(2), e1755.